Generation of <i>α</i>Gal-enhanced bifunctional tumor vaccine.

Jian HE; Yu Huo; Zhikun Zhang; Yiqun Luo; Xiuli Liu; Qiaoying Chen; Pan WU; Wei Shi; Tao WU; Chao Tang; Huixue Wang; Lan LI; Xiyu Liu; Yong Huang; Yongxiang Zhao; Lu Gan; Bing Wang; Liping Zhong

Return

Generation of αGal-enhanced bifunctional tumor vaccine.

Author: Jian HE ¹ ; Yu HUO ¹ ; Zhikun ZHANG ¹ ; Yiqun LUO ¹ ; Xiuli LIU ¹ ; Qiaoying CHEN ¹ ; Pan WU ¹ ; Wei SHI ² ; Tao WU ³ ; Chao TANG ¹ ; Huixue WANG ¹ ; Lan LI ¹ ; Xiyu LIU ¹ ; Yong HUANG ¹ ; Yongxiang ZHAO ¹ ; Lu GAN ¹ ; Bing WANG ⁴ ; Liping ZHONG ¹
Author Information

1. National Center for International Research of Biotargeting Theranostics, Guangxi Key Laboratory of Biotargeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Biotargeting Theranostics, Guangxi Medical University, Nanning 530021, China.
2. The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning 530023, China.
3. The First People's Hospital of Changde City, Changde 415003, China.
4. Department of Spine Surgery, the Second Xiangya Hospital of Central South University, Changsha 410011, China.
Publication Type:Journal Article
Keywords: Cytotoxic T lymphocytes; Dendritic cells; Endoglin; Fusion cells; Hepatocellular carcinoma; Immunotherapy; Tumor neovascular endothelial cells; αGal
From: Acta Pharmaceutica Sinica B 2022;12(7):3177-3186
CountryChina
Language:English
Abstract: Hepatocellular carcinoma (HCC) is a common malignant tumor with poor prognosis and high mortality. In this study, we demonstrated a novel vaccine targeting HCC and tumor neovascular endothelial cells by fusing recombinant MHCC97H cells expressing porcine α-1,3-galactose epitopes (αGal) and endorphin extracellular domains (END) with dendritic cells (DCs) from healthy volunteers. END⁺/Gal⁺-MHCC97H/DC fusion cells induced cytotoxic T lymphocytes (CTLs) and secretion of interferon-gamma (IFN-γ). CTLs targeted cells expressing αGal and END and tumor angiogenesis. The fused cell vaccine can effectively inhibit tumor growth and prolong the survival time of human hepatoma mice, indicating the high clinical potential of this new cell based vaccine.